Becton, Dickinson and Company (BDX) Shares Sold by Horan Capital Management

Horan Capital Management cut its position in Becton, Dickinson and Company (NYSE:BDX) by 5.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,922 shares of the medical instruments supplier’s stock after selling 542 shares during the period. Horan Capital Management’s holdings in Becton, Dickinson and were worth $1,935,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. BlackRock Inc. increased its position in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the period. Vanguard Group Inc. increased its position in Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares during the period. Point72 Asset Management L.P. purchased a new position in Becton, Dickinson and during the first quarter worth about $101,993,000. Waverton Investment Management Ltd purchased a new position in Becton, Dickinson and during the second quarter worth about $68,448,000. Finally, Cantillon Capital Management LLC increased its position in Becton, Dickinson and by 30.3% in the first quarter. Cantillon Capital Management LLC now owns 1,344,427 shares of the medical instruments supplier’s stock worth $246,622,000 after buying an additional 312,926 shares during the period. 75.42% of the stock is owned by institutional investors.

Shares of Becton, Dickinson and Company (BDX) traded down 0.41% during trading on Monday, hitting $199.80. The stock had a trading volume of 615,041 shares. The stock has a 50-day moving average price of $190.01 and a 200 day moving average price of $181.27. The company has a market cap of $42.62 billion, a P/E ratio of 33.18 and a beta of 1.05. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $201.30.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.23 by $0.07. The firm had revenue of $2.97 billion during the quarter, compared to analyst estimates of $2.92 billion. Becton, Dickinson and had a return on equity of 25.37% and a net margin of 10.67%. The business’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.18 EPS. Equities analysts expect that Becton, Dickinson and Company will post $9.45 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, June 30th. Stockholders of record on Friday, June 9th were given a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 1.46%. The ex-dividend date of this dividend was Wednesday, June 7th. Becton, Dickinson and’s payout ratio is 48.26%.

ILLEGAL ACTIVITY WARNING: This report was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/2723212/becton-dickinson-and-company-bdx-shares-sold-by-horan-capital-management.html.

A number of equities analysts have issued reports on BDX shares. Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $186.00 to $200.00 in a report on Monday, April 24th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Jefferies Group LLC reiterated a “buy” rating and issued a $200.00 price objective on shares of Becton, Dickinson and in a report on Wednesday, March 29th. Finally, Royal Bank Of Canada reiterated a “hold” rating and issued a $177.00 price objective on shares of Becton, Dickinson and in a report on Thursday, April 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $192.17.

In other news, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the transaction, the vice president now directly owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback


Leave a Reply

© 2006-2017 Ticker Report. Google+.